Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.

Velloso FJ, Bianco AF, Farias JO, Torres NE, Ferruzo PY, Anschau V, Jesus-Ferreira HC, Chang TH, Sogayar MC, Zerbini LF, Correa RG.

Onco Targets Ther. 2017 Nov 20;10:5491-5524. doi: 10.2147/OTT.S142154. eCollection 2017. Review.

2.

The role of BRCA status on prognosis in patients with triple-negative breast cancer.

Xie Y, Gou Q, Wang Q, Zhong X, Zheng H.

Oncotarget. 2017 Aug 3;8(50):87151-87162. doi: 10.18632/oncotarget.19895. eCollection 2017 Oct 20.

3.

Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution.

Serrano-Gómez SJ, Fejerman L, Zabaleta J.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):3-10. doi: 10.1158/1055-9965.EPI-17-0420. Epub 2017 Oct 20. Review.

PMID:
29054978
4.

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.

Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fujiwara Y, Tsuda H, Tamura K.

ESMO Open. 2017 May 2;2(2):e000150. doi: 10.1136/esmoopen-2016-000150. eCollection 2017.

5.

BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.

Godet I, Gilkes DM.

Integr Cancer Sci Ther. 2017 Feb;4(1). doi: 10.15761/ICST.1000228. Epub 2017 Feb 27.

6.

Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer.

Kim S, Park S, Cho MS, Lim W, Moon BI, Sung SH.

J Cancer. 2017 Jan 1;8(1):124-130. doi: 10.7150/jca.17437. eCollection 2017.

7.

Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.

Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK, Kim SW.

Curr Oncol. 2016 Oct;23(5):298-303. Epub 2016 Oct 25.

8.

Mammary gland stem cells and their application in breast cancer.

Yang X, Wang H, Jiao B.

Oncotarget. 2017 Feb 7;8(6):10675-10691. doi: 10.18632/oncotarget.12893. Review.

9.

Triple-negative breast cancer: treatment challenges and solutions.

Collignon J, Lousberg L, Schroeder H, Jerusalem G.

Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.

10.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.

Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17. Review.

11.

Breed- and age-related differences in canine mammary tumors.

Kim HW, Lim HY, Shin JI, Seung BJ, Ju JH, Sur JH.

Can J Vet Res. 2016 Apr;80(2):146-55.

12.

Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.

Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS.

PLoS One. 2016 Apr 14;11(4):e0153113. doi: 10.1371/journal.pone.0153113. eCollection 2016.

13.

MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.

Matamala N, Vargas MT, González-Cámpora R, Arias JI, Menéndez P, Andrés-León E, Yanowsky K, Llaneza-Folgueras A, Miñambres R, Martínez-Delgado B, Benítez J.

Oncotarget. 2016 Apr 12;7(15):20068-79. doi: 10.18632/oncotarget.7705.

14.

An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.

Holm K, Staaf J, Lauss M, Aine M, Lindgren D, Bendahl PO, Vallon-Christersson J, Barkardottir RB, Höglund M, Borg Å, Jönsson G, Ringnér M.

Breast Cancer Res. 2016 Feb 29;18(1):27. doi: 10.1186/s13058-016-0685-5.

15.

BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1.

Zhang W, Luo J, Yang F, Wang Y, Yin Y, Strom A, Gustafsson JÅ, Guan X.

Sci Rep. 2016 Feb 23;6:22034. doi: 10.1038/srep22034.

16.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

17.

Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer.

Olsson E, Winter C, George A, Chen Y, Törngren T, Bendahl PO, Borg Å, Gruvberger-Saal SK, Saal LH.

PLoS One. 2015 Dec 15;10(12):e0144528. doi: 10.1371/journal.pone.0144528. eCollection 2015.

18.

Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.

Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K, Lee HJ, Eggebeen R, Sawitzke J, Bass S, Zhang X, Robles V, Hollis C, Barajas C, Rath E, Arentz C, Figueroa JA, Nguyen DD, Nahleh Z.

Gigascience. 2015 Nov 4;4:50. doi: 10.1186/s13742-015-0088-z. eCollection 2015.

19.

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.

Fkih M'hamed I, Privat M, Ponelle F, Penault-Llorca F, Kenani A, Bignon YJ.

Cell Oncol (Dordr). 2015 Dec;38(6):433-42. doi: 10.1007/s13402-015-0239-3. Epub 2015 Sep 21.

20.

Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.

Yehia L, Boulos F, Jabbour M, Mahfoud Z, Fakhruddin N, El-Sabban M.

PLoS One. 2015 Jun 5;10(6):e0129356. doi: 10.1371/journal.pone.0129356. eCollection 2015.

Supplemental Content

Support Center